| VERtebral Fracture Treatment Comparisons in Osteoporotic Women (NCT01709110) | Eli Lilly and Company | 2012-10-01 |
| Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA) (NCT01676701) | Eli Lilly and Company | 2012-09-01 |
| A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants (NCT01688635) | Eli Lilly and Company | 2012-09-01 |
| A Study of LY2940680 in Healthy Participants (NCT01681186) | Eli Lilly and Company | 2012-09-01 |
| A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression (NCT01687478) | Eli Lilly and Company | 2012-09-01 |
| A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease (NCT01683409) | Eli Lilly and Company | 2012-08-01 |
| A Study of Dulaglutide in Chinese Participants (NCT01667900) | Eli Lilly and Company | 2012-08-01 |
| A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin (NCT01606748) | Eli Lilly and Company | 2012-08-01 |
| A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors (NCT01624467) | Eli Lilly and Company | 2012-08-01 |
| A Study of LY3015014 in Healthy Participants With High Cholesterol (NCT01671085) | Eli Lilly and Company | 2012-08-01 |
| A Study of LY3023414 in Participants With Advanced Cancer (NCT01655225) | Eli Lilly and Company | 2012-07-31 |
| A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) (NCT01646177) | Eli Lilly and Company | 2012-07-28 |
| A Study of LY3006072 in Healthy Participants (NCT01640249) | Eli Lilly and Company | 2012-07-24 |
| A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors (NCT01515306) | Eli Lilly and Company | 2012-07-19 |
| A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension (NCT01484431) | Eli Lilly and Company | 2012-07-17 |
| A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) (NCT01621178) | Eli Lilly and Company | 2012-07-01 |
| A Study of IMC-TR1 in Participants With Advanced Solid Tumors (NCT01646203) | Eli Lilly and Company | 2012-07-01 |
| A Study of LY2963016 in Healthy Participants (NCT01634165) | Eli Lilly and Company | 2012-07-01 |
| A Study LY2228820 for Recurrent Ovarian Cancer (NCT01663857) | Eli Lilly and Company | 2012-07-01 |
| A Study of LY2605541 Versus Insulin Glargine on Blood Sugar (NCT01654380) | Eli Lilly and Company | 2012-07-01 |
| A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors (NCT01567163) | Eli Lilly and Company | 2012-07-01 |
| Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma (NCT01556438) | Eli Lilly and Company | 2012-07-01 |
| A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus (NCT01648582) | Eli Lilly and Company | 2012-07-01 |
| A Study of Prasugrel in Healthy Participants (NCT01648790) | Eli Lilly and Company | 2012-07-01 |
| A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) (NCT01602224) | Eli Lilly and Company | 2012-07-01 |
| Study of LY2409021 in Participants With Type 1 Diabetes (NCT01640834) | Eli Lilly and Company | 2012-07-01 |
| A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus (NCT01644500) | Eli Lilly and Company | 2012-07-01 |
| A Study of LY2951742 in Participants With Migraine (NCT01625988) | Eli Lilly and Company | 2012-06-28 |
| Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms (NCT01520220) | Eli Lilly and Company | 2012-06-11 |
| A Study in Japanese Participants With Moderate-to-Severe Psoriasis (NCT01624233) | Eli Lilly and Company | 2012-06-01 |
| A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol (NCT01618916) | Eli Lilly and Company | 2012-06-01 |
| A Single Dose Study of LY3023703 in Healthy Participants (NCT01632579) | Eli Lilly and Company | 2012-06-01 |
| A Multiple-dose Study of LY3031207 in Healthy Participants (NCT01632566) | Eli Lilly and Company | 2012-06-01 |
| A Study of LY2875358 in Japanese Participants With Advanced Cancer (NCT01602289) | Eli Lilly and Company | 2012-06-01 |
| A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes (NCT01624259) | Eli Lilly and Company | 2012-06-01 |
| An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057) (NCT01621191) | Eli Lilly and Company | 2012-06-01 |
| A Study of LY2784544 in Participants With Myeloproliferative Neoplasms (NCT01594723) | Eli Lilly and Company | 2012-05-22 |
| A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) (NCT01597245) | Eli Lilly and Company | 2012-05-18 |
| A Study of LY2127399 in Rheumatoid Arthritis (NCT01576549) | Eli Lilly and Company | 2012-05-01 |
| A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus (NCT01582451) | Eli Lilly and Company | 2012-05-01 |
| A Study in Older Participants Who Have Fallen and Have Muscle Weakness (NCT01604408) | Eli Lilly and Company | 2012-05-01 |
| A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus (NCT01600950) | Eli Lilly and Company | 2012-05-01 |
| A Study in Recurrent Glioblastoma (GB) (NCT01582269) | Eli Lilly and Company | 2012-04-26 |
| The Effects of LY2409021 on the Liver (NCT01588366) | Eli Lilly and Company | 2012-04-01 |
| A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus (NCT01584232) | Eli Lilly and Company | 2012-04-01 |
| A Study of LY110140 in Healthy Japanese Male Participants (NCT01569126) | Eli Lilly and Company | 2012-04-01 |
| A Study of LY3016859 in Healthy Volunteers (NCT01545583) | Eli Lilly and Company | 2012-04-01 |
| A Study of LY2784544 in Healthy Male Subjects (NCT01577355) | Eli Lilly and Company | 2012-04-01 |
| A Study of LY2979165 and LY2140023 in Healthy Volunteers (NCT01524237) | Eli Lilly and Company | 2012-04-01 |
| Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia (NCT01556594) | Eli Lilly and Company | 2012-03-01 |
| A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus (NCT01558271) | Eli Lilly and Company | 2012-03-01 |
| Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease (NCT01561430) | Eli Lilly and Company | 2012-03-01 |
| A Study of Duloxetine in Fibromyalgia (NCT01552057) | Eli Lilly and Company | 2012-03-01 |
| A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe (NCT01524770) | Eli Lilly and Company | 2012-03-01 |
| A Study of LY2484595 on the Electrical Activity of the Heart (NCT01537887) | Eli Lilly and Company | 2012-02-01 |
| A Study of LY3009104 in Healthy Participants (NCT01536951) | Eli Lilly and Company | 2012-02-01 |
| A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) (NCT01469000) | Eli Lilly and Company | 2012-02-01 |
| Effect of Teriparatide on Hip Fracture Healing (NCT01473589) | Eli Lilly and Company | 2012-02-01 |
| A Study of LY2886721 in Healthy Participants (NCT01534273) | Eli Lilly and Company | 2012-02-01 |
| A Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Participants (NCT01515358) | Eli Lilly and Company | 2012-02-01 |
| A Study of LY3025876 in Healthy Volunteers (NCT01528124) | Eli Lilly and Company | 2012-02-01 |
| A Study in Participants With Type I Diabetes Mellitus (NCT01454284) | Eli Lilly and Company | 2012-01-01 |
| A Study in Participants With Type 1 Diabetes Mellitus (NCT01481779) | Eli Lilly and Company | 2012-01-01 |
| Second Study of the Effect of Teriparatide on Hip Fracture Healing (NCT01473602) | Eli Lilly and Company | 2012-01-01 |
| On Open-Label Study in Participants With Systemic Lupus Erythematosus (NCT01488708) | Eli Lilly and Company | 2012-01-01 |
| A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis (NCT01490632) | Eli Lilly and Company | 2011-12-01 |
| A Non-drug Methods Study in Participants With Alzheimer's Disease (NCT01459016) | Eli Lilly and Company | 2011-12-01 |
| A Study of LY3007113 in Participants With Advanced Cancer (NCT01463631) | Eli Lilly and Company | 2011-12-01 |
| A Long-Term Study in Schizophrenia (NCT01487083) | Eli Lilly and Company | 2011-12-01 |
| A Study in Participants With Type 2 Diabetes Mellitus (NCT01468987) | Eli Lilly and Company | 2011-12-01 |
| Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH) (NCT01460342) | Eli Lilly and Company | 2011-12-01 |
| A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer (NCT01505530) | Eli Lilly and Company | 2011-12-01 |
| Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy (NCT01474538) | Eli Lilly and Company | 2011-12-01 |
| A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (NCT01473563) | Eli Lilly and Company | 2011-12-01 |
| A Phase 3 Study in Participants With Moderate to Severe Psoriasis (NCT01474512) | Eli Lilly and Company | 2011-11-16 |
| A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma (NCT01432951) | Eli Lilly and Company | 2011-11-01 |
| A Study in Patients With Type 2 Diabetes Mellitus (NCT01435616) | Eli Lilly and Company | 2011-11-01 |
| Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy (NCT01469013) | Eli Lilly and Company | 2011-11-01 |
| A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (NCT01476696) | Eli Lilly and Company | 2011-11-01 |
| A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer (NCT01427933) | Eli Lilly and Company | 2011-11-01 |
| A First-in-Human Study of LY3009385 in Healthy Participants (NCT01477567) | Eli Lilly and Company | 2011-11-01 |
| A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants (NCT01476345) | Eli Lilly and Company | 2011-11-01 |
| A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus (NCT01468181) | Eli Lilly and Company | 2011-11-01 |
| A Study of LY3031207 in Healthy Subjects (NCT01449630) | Eli Lilly and Company | 2011-10-24 |
| A Study to Evaluate the Effect of Genotype on LY2216684 (NCT01460381) | Eli Lilly and Company | 2011-10-01 |
| A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants (NCT01458210) | Eli Lilly and Company | 2011-10-01 |
| A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart (NCT01460368) | Eli Lilly and Company | 2011-10-01 |
| A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults (NCT02778113) | Eli Lilly and Company | 2011-10-01 |
| A Study of LY2484595 on Pharmacokinetics in Healthy Participants (NCT01448824) | Eli Lilly and Company | 2011-10-01 |
| A Study of LY2484595 in Healthy Subjects (NCT01450098) | Eli Lilly and Company | 2011-10-01 |
| A Study to Evaluate the Effect of Clarithromycin on LY2216684 (NCT01460407) | Eli Lilly and Company | 2011-10-01 |
| A Study of Lasmiditan on the Heart in Healthy Participants (NCT03465436) | Eli Lilly and Company | 2011-09-16 |
| A Study of LY2623091 in Male and Females With Chronic Kidney Disease (NCT01427972) | Eli Lilly and Company | 2011-09-01 |
| A Study in Patients With Type 2 Diabetes (NCT01408095) | Eli Lilly and Company | 2011-09-01 |
| A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet (NCT01430091) | Eli Lilly and Company | 2011-09-01 |
| A Study in Adults With Type 2 Diabetes (NCT01421459) | Eli Lilly and Company | 2011-09-01 |
| A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants (NCT01432938) | Eli Lilly and Company | 2011-09-01 |
| The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects (NCT01440478) | Eli Lilly and Company | 2011-09-01 |
| A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants (NCT01436201) | Eli Lilly and Company | 2011-09-01 |
| A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol (NCT01426412) | Eli Lilly and Company | 2011-09-01 |